Taking into account that HSPs and immune checkpoints are associated with T cell activation and that current and emerging treatments of lymphoma patients include immune checkpoint inhibitors, we have also assessed the effect of a combined blockade of HSP90 and immune checkpoints (PD-1 and CTLA-4) in vitro. Here, HSP90AB1 is linked to lymphoma.